Stay well informed

Investor News

We would like to inform you about the current business development of HAEMATO AG as well as about our investor relations activities.

Investor News

HAEMATO PHARM GmbH ("HAEMATO"), a 100% subsidiary of HAEMATO AG (ISIN: DE000289VV1), is expanding its medical device portfolio in the fight against Corona virus. In addition to the already introduced Point-of-Care (PoC) PCR device, HAEMATO is now also marketing the Mini Dock, an alternative PoC device that sets a benchmark in terms of price.

Investor News

With the current omicron wave, laboratories in Germany are facing a sharp increase in PCR testing. The evaluation capacities are pushing increasingly towards their limits, especially with regards to the new quarantine regulations.

In operational terms, HAEMATO AG is heading for a record year following the acquisition of M1 Aesthetics GmbH. In addition, the expansion of their private label business is increasingly coming into focus. In this regard, the company plans to expand its portfolio with a botulinum toxin product under its own brand. GBC analyst Cosmin Filker spoke …

Investor News

HAEMATO continues to grow: consolidated revenue in the third quarter of 2021 increased by 9% year-over-year to EUR 65.1 million. From 1 January to 30 September 2021, consolidated revenue rose to 216.6 million euros. This corresponds to a growth of 23 % compared to the same period of the previous year. Group EBIT increased to 1.4 million euros in …

Ad-Hoc Mitteilung

Seoul and Schönefeld, 25th October 2021 - HAEMATO PHARM GmbH ("HAEMATO"), a wholly owned subsidiary of HAEMATO AG (ISIN: DE000289VV1) is expanding its own portfolio with a botulinum toxin product from the pharmaceutical company Huons BioPharma Co., Ltd. ("Huons BioPharma"), based in Seoul, Korea. For this purpose, Huons BioPharma and HAEMATO have …

Investor News

Seoul and Schönefeld, 25th October 2021 - HAEMATO PHARM GmbH ("HAEMATO"), a wholly owned subsidiary of HAEMATO AG (ISIN: DE000289VV1), is expanding its own portfolio with a botulinum toxin product from the pharmaceutical company Huons Bio Pharma Co., Ltd. ("Huons BioPharma"), based in Seoul, Korea. For this purpose, Huons BioPharma and HAEMATO have …

For investors

Do you have any further questions about the group? Our investor relations team is happy to help you..

Contact us